Objectives To assess the safety of synthetic (s) and biological (b) disease-modifying
antirheumatic drugs (DMARDs) for the management of rheumatoid arthritis (RA) to inform …

The elderly rheumatoid arthritis (RA) population consists of both elderly-onset RA that
manifests after the age of 60 and individuals diagnosed with RA early in life who age …

Rheumatoid arthritis (RA) is a chronic inflammatory condition that can result in pain and
functional disability. It is also associated with an increased occurrence of comorbidities …

The beginning of the 21st century saw a biopharmaceutical revolution in the treatment of
inflammatory rheumatic diseases, particularly rheumatoid arthritis. The fast-evolving use of …

Objectives In daily practice, safety in rheumatoid arthritis (RA) patients receiving biological
treatment is an important issue. Unlike randomized controlled trials, biologic registers …

Objectives To detail the greatest areas of unmet scientific and clinical needs in
rheumatology. Methods The 21st annual international Advances in Targeted Therapies …

Abstract Background In European axial spondyloarthritis (axSpA) and psoriatic arthritis
(PsA) clinical registries, we aimed to investigate commonalities and differences in (1) set-up …

Background Biological agents that contain substances affecting the immune system are
increasingly being used to treat chronic inflammatory systemic diseases. Aside from the …

Rheumatoid arthritis (RA) is one of the most common rheumatic conditions, impacting quality
of life on several domains. Major breakthroughs have been achieved over the past three …

Objectives To evaluate the rate of tuberculosis (TB) in biologic users for rheumatic diseases
in South Africa, the effectiveness of our latent TB infection (LTBI) programme, risk factors and …